Posted on 26/05/2010 in Pharmaceutical Company Product News Eisai Limited has confirmed that it will attend the annual meeting of the American Society of Clinical Oncology (ASCO) next month, where it will present data on its oncology pipeline.
The pharmaceutical company intends to present 15 abstracts on clinical trials for a number of compounds from its drug development portfolio, including treatments for metastatic breast cancer, T-cell lymphoma and non-small cell lung cancer.
Among these will be an analysis of results from the Embrace study, a phase III trial of the breast cancer treatment eribulin mesylate which compared the performance of the drug to different therapies.
The drug was submitted to the European Medicines Agency for regulatory approval earlier this year.
Eisai states that these studies will be illustrative of its approach to integrative oncology as a key area of therapeutic focus.
It added: "Eisai will continue its commitment to actively pursuing the global discovery, development and production of oncology therapies representative of its human healthcare philosophy to increase benefits to patients and their families."Other news stories from 26/05/2010
Read more in the Zenopa News Archive
How this news is generated
|
